Zobrazeno 1 - 10
of 31
pro vyhledávání: '"Nobuki, Furubayashi"'
Autor:
Motonobu Nakamura, Naotaka Sakamoto, Narihito Seki, Nobuki Furubayashi, Toshihisa Tomoda, YooHyun Song, Yoshifumi Hori, Kentaro Kuroiwa, Shingo Tamura, Akinori Minato, Takahito Negishi, Naohiro Fujimoto
Publikováno v:
Cancer Management and Research
Nobuki Furubayashi,1 Akinori Minato,2 Takahito Negishi,1 Naotaka Sakamoto,3 Yoohyun Song,4 Yoshifumi Hori,5 Toshihisa Tomoda,6 Shingo Tamura,7 Kentaro Kuroiwa,5 Narihito Seki,4 Naohiro Fujimoto,2 Motonobu Nakamura1 1Department of Urology, National Ho
Autor:
Nobuki Furubayashi, Taichi Matsubara, Ryo Toyozawa, Takahito Negishi, Kensaku Ito, Tatsuro Okamoto, Takashi Seto, Takatoshi Fujishita, Shinkichi Takamori, Motonobu Nakamura, Kenichi Taguchi, Masafumi Yamaguchi
Publikováno v:
Thoracic Cancer
Thoracic Cancer, Vol 12, Iss 14, Pp 2122-2125 (2021)
Thoracic Cancer, Vol 12, Iss 14, Pp 2122-2125 (2021)
Immune checkpoint inhibitors (ICIs) have become the standard of care for the treatment of non‐small cell lung cancer (NSCLC). With the increasing use of ICIs, clinicians should be familiar with their immune‐related adverse events, including sarco
Autor:
Eijiro Okajima, Motonobu Nakamura, Naotaka Nishiyama, Narihito Seki, Yoshifumi Hori, Nobuki Furubayashi, Tohru Nakagawa, Kentarou Kuroiwa, Toshihisa Tomoda, Takahito Negishi, Hiroshi Kitamura, Yuhyon Son
Publikováno v:
Anticancer Research. 41:1539-1545
Background/aim Nivolumab monotherapy for advanced/metastatic renal cell carcinoma (RCC) shows a survival benefit. The purpose of this study was to evaluate tumor responses to nivolumab in various metastatic and primary sites in patients with RCC. Pat
Publikováno v:
Research and Reports in Urology
Nobuki Furubayashi, Takahito Negishi, Akihiro Miura, Nobutaka Nakamura, Motonobu Nakamura Department of Urology, National Hospital Organization Kyushu Cancer Center, Fukuoka, JapanCorrespondence: Nobuki Furubayashi Tel +81-92-541-3231Fax +81-92-551-4
Autor:
Masatoshi Kumagai, Nobuki Furubayashi, Toshihisa Tomoda, Yoshifumi Hori, Noriaki Tokuda, Motonobu Nakamura, Futoshi Morokuma, Tomohiro Inoue, Takahito Negishi, Kentaro Kuroiwa
Publikováno v:
Journal of Clinical Medicine Research
Background: Since December 2017, pembrolizumab has been approved in Japan as a second-line treatment for radical unresectable urothelial carcinoma (UC) that has become exacerbated after chemotherapy by the international randomized phase 3 trial, KEYN
Autor:
Narihito Seki, Yoshifumi Hori, Takahito Negishi, Naotaka Sakamoto, Nobuki Furubayashi, YooHyun Song, Toshihisa Tomoda, Futoshi Morokuma, Shingo Tamura, Kentaro Kuroiwa, Motonobu Nakamura
Publikováno v:
In Vivo
Background/aim Despite the presence of a mixed response (MR) in patients with urothelial carcinoma (UC) who receive immune checkpoint inhibitors, the clinical outcome of these patient has not been reported. We evaluated the clinical outcome of MR to
Autor:
Akihiro Miura, Takahito Negishi, Nobuki Furubayashi, Kenichi Taguchi, Motonobu Nakamura, Yoshiaki Sato
Background: Mucinous tubular and spindle cell carcinoma (MTSCC) is a rare subtype of renal cell carcinoma (RCC) and generally considered a low-grade renal epithelial neoplasm composed of tubules, spindle cells, and extracellular mucin. MTSCC with dis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cb2000743adb4a4d6ca3357e05e0f26f
https://doi.org/10.21203/rs.3.rs-386219/v1
https://doi.org/10.21203/rs.3.rs-386219/v1
Autor:
Narihito Seki, Futoshi Morokuma, Yoshifumi Hori, Noriaki Tokuda, Nobuki Furubayashi, Toshihisa Tomoda, Naotaka Sakamoto, Takahito Negishi, Hozumi Shimokawa, YooHyun Song, Motonobu Nakamura, Kentaro Kuroiwa
Publikováno v:
OncoTargets and therapy
Nobuki Furubayashi,1 Takahito Negishi,1 Naotaka Sakamoto,2 Hozumi Shimokawa,3 Futoshi Morokuma,4 Yoohyun Song,5 Yoshifumi Hori,6 Toshihisa Tomoda,7 Noriaki Tokuda,4 Narihito Seki,5 Kentaro Kuroiwa,6 Motonobu Nakamura1 1Department of Urology, National
Autor:
Futoshi Morokuma, Masatoshi Kumagai, Yoshifumi Hori, Tomohiro Inoue, Nobuki Furubayashi, Takahito Negishi, Toshihisa Tomoda, Kentaro Kuroiwa, Motonobu Nakamura, Noriaki Tokuda
Publikováno v:
Molecular and Clinical Oncology
Pembrolizumab has been available for the treatment of radical resectable urothelial carcinoma (UC) when it is exacerbated after chemotherapy since December 2017 in Japan. However, the efficacy of chemotherapy for cases progressing after pembrolizumab
Autor:
Noriaki Tokuda, Yoshifumi Hori, Motonobu Nakamura, Nobutaka Nakamura, Kentaro Kuroiwa, Akihiro Miura, Nobuki Furubayashi, Toshihisa Tomoda, Futoshi Morokuma, Yoshiaki Sato, Takahito Negishi
BackgroundTo evaluate the optimal timing of sequencing from platinum-based chemotherapy to pembrolizumab with advanced urothelial carcinoma (UC) in real-world clinical practice.MethodsA total of 34 patients who received pembrolizumab as second-line t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a1679f370aca00e2ac6364cd651feb20
https://doi.org/10.21203/rs.3.rs-116673/v1
https://doi.org/10.21203/rs.3.rs-116673/v1